A statistical difference was found in the CD4+ (p = 0.0038) and CD45+ (p = 0.0465) tumor-infiltrating immune cell percentages, platelet count (p = 0.0408), and ASA performance scores (p = 0.0217) of the patients. The gene discussed is PTPRC; the disease is neoplasm.